Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Guelph

$17,500.00

Therapeutic potential of VANL-100 explored in cellular models of Alzheimer’s disease

EF 2023-24

Résumé
In Alzheimer's disease (AD), oxidative stress and abnormal accumulation of the protein beta-amyloid is observed. Oxidative stress occurs when there is an imbalance between harmful oxygen-containing compounds known as reactive oxygen species, and the antioxidants that prevent them from damaging cells in the body. Interestingly, oxidative stress has been implicated in beta-amyloid accumulation in the brain and its accumulation generates additional oxidative stress. Current treatments for AD focus on symptom relief but fail to target the root cause. Given the association between oxidative stress and AD pathology, antioxidants could be effective in the prevention and treatment of AD. Previous studies have explored dietary antioxidants in the prevention and progression of AD, but the results have been mixed, with the combined use of antioxidants showing more promising results than a single antioxidant. Recently, research involving new compounds formed by chemically linking antioxidants has shown that these drug conjugates are even more potent at decreasing oxidative stress. Although research on the topic is limited, results indicate they have therapeutic potential. The main objective of the proposed study is to determine whether the new drug called VANL-100, an antioxidant co-drug synthesized from naringenin and alpha lipoic acid, can provide neuroprotective effects against oxidative stress and neurotoxicity. Using a cellular model of AD, the antioxidant capacity and neuroprotective potential of VANL-100 will be compared to its parent compounds. This research will provide insight into the neuroprotective properties of antioxidant conjugate drugs and their potential therapeutic effects in targeting oxidative stress and neurotoxicity that contribute to the pathology of AD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
505926
Name
CHEN HELEN
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Therapeutic potential of VANL-100 explored in cellular models of Alzheimer’s disease
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aging; Alpha-Lipoic Acid; Alzheimer'S Disease; Antioxidant; Beta-Amyloid; Naringenin; Neurodegeneration; Oxidative Stress; Vanl-100; ß-Site Amyloid Precursor Protein Cleaving Enzyme 1
Abstract
In Alzheimer's disease (AD), oxidative stress and abnormal accumulation of the protein beta-amyloid is observed. Oxidative stress occurs when there is an imbalance between harmful oxygen-containing compounds known as reactive oxygen species, and the antioxidants that prevent them from damaging cells in the body. Interestingly, oxidative stress has been implicated in beta-amyloid accumulation in the brain and its accumulation generates additional oxidative stress. Current treatments for AD focus on symptom relief but fail to target the root cause. Given the association between oxidative stress and AD pathology, antioxidants could be effective in the prevention and treatment of AD. Previous studies have explored dietary antioxidants in the prevention and progression of AD, but the results have been mixed, with the combined use of antioxidants showing more promising results than a single antioxidant. Recently, research involving new compounds formed by chemically linking antioxidants has shown that these drug conjugates are even more potent at decreasing oxidative stress. Although research on the topic is limited, results indicate they have therapeutic potential. The main objective of the proposed study is to determine whether the new drug called VANL-100, an antioxidant co-drug synthesized from naringenin and alpha lipoic acid, can provide neuroprotective effects against oxidative stress and neurotoxicity. Using a cellular model of AD, the antioxidant capacity and neuroprotective potential of VANL-100 will be compared to its parent compounds. This research will provide insight into the neuroprotective properties of antioxidant conjugate drugs and their potential therapeutic effects in targeting oxidative stress and neurotoxicity that contribute to the pathology of AD.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
CHEN, HELEN
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~